535 Mission St Floor 14 San Francisco, CA, 94105 2997 United StatesOpenBench provides high quality small molecule discovery services through a unique service model we call Success-Driven Molecular Discovery. OpenBench bears the cost and scientific risk of early discovery, so the first dollar you spend is to purchase potent hits and leads. Our ability to perform fast and focused screens of massive, diverse, lead-like chemical spaces enables us to identify, synthesize, and confirm potent, progressable compounds that are distinct from prior art and poised for optimization. The core technology that enables Success-Driven Molecular Discovery is OpenBench’s structure-based machine learning platform. The OpenBench platform has succeeded in finding high-quality, actionable chemical matter for more than 90% of targets we have taken on to date. OpenBench has a track record of drugging challenging targets, with over half of our commercial projects pursuing allosteric or non-functional binding sites, in many cases with no small molecule prior art. An OpenBench collaboration begins with a one-week, no cost assessment of your binding hypothesis. Since we bear the risk, we won’t waste your time and our money on campaigns that are not a good fit for the OpenBench platform. Pricing is transparent and biotech-friendly: we establish all fees prior to start of work, and your obligation to pay hinges upon our achievement of your pre-defined potency, novelty, and developability criteria. When we conclude a collaboration, you purchase developed chemical IP outright to optimize and commercialize as you please––we prefer not to incur any milestones or royalties. The OpenBench staff has a wealth of scientific, technical, and operational experience in early discovery. By combining our knowledge and scientific rigor with world-class customer service and a high degree of accountability bred by the success-driven model, we strive to offer the most biotech-friendly early discovery offering on the planet.